Skip to main content

Day: November 8, 2023

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

TPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC study New capital strengthens balance sheet and extends cash runway into 2025BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We were extremely pleased to see the pronounced external validation of the new data showing the clear benefit of TPST-1120 combination therapy compared to standard of care in first-line liver cancer,” said Stephen Brady, president and chief executive officer of Tempest. “The data have not only...

Continue reading

Atlanticus Reports Third Quarter 2023 Financial Results

Third Quarter 2023 Receivables growth of 18.1% over prior year, with over 3.4 million accounts served (1), allowing for continued strong results ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company which enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced its financial results for the third quarter ended September 30, 2023. An accompanying earnings presentation is available in the Investors section of the Company’s website at www.atlanticus.com or by clicking [here]. Financial and Operating Highlights Third Quarter 2023 Highlights (all comparisons to the Third Quarter 2022)Managed receivables2 increased 12.9% to $2.3 billion Total...

Continue reading

Osisko Declares Fourth Quarter 2023 Dividend

MONTREAL, Nov. 08, 2023 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (OR: TSX & NYSE) is pleased to announce a fourth quarter 2023 dividend of C$0.06 per common share. The dividend will be paid on January 15, 2024 to shareholders of record as of the close of business on December 29, 2023. This dividend is an “eligible dividend” as defined in the Income Tax Act (Canada). For shareholders residing in the United States, the U.S. dollar equivalent will be determined based on the daily rate published by the Bank of Canada on December 29, 2023. The Company also wishes to remind its shareholders that it has implemented a dividend reinvestment plan (the “Plan”). Shareholders who are residents of Canada and the United States may elect to participate in the Plan in connection with the dividend...

Continue reading

Firm Capital Apartment REIT Reports Q3/2023 Results and Provides Strategic Review Update

All figures in $USD unless otherwise noted. TORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) — Firm Capital Apartment Real Estate Investment Trust (“the “Trust”), (TSXV: FCA.U), (TSXV: FCA.UN) is pleased to report its financial results for the three and nine months ended September 30, 2023 as well as provide an update regarding the previously announced Strategic Review: EARNINGSFor the three months ended September 30, 2023, net loss was approximately $1.5 million, in comparison to the $1.9 million net loss reported for the three months ended June 30, 2023 and the $1.4 million net loss reported for the three months ended September 30, 2022; Excluding non-cash fair value adjustments, net loss was $0.4 million for the three months ended September 30, 2023, in comparison to the $0.2 million net loss reported for the three months ended June...

Continue reading

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that it will participate at the following upcoming medical and investor conferences in November: American College of Allergy, Asthma, and Immunology (ACAAI) 2023 Annual Scientific MeetingConference Dates: November 9-13, 2023Abstract Title: Briquilimab, an anti-CD117 antibody, prevents passive systemic anaphylaxis in mice expressing chimeric human/mouse...

Continue reading

SANUWAVE Will Host a Conference Call on November 10, 2023 at 8:00 AM (ET) to Present the Q3 2023 Financial Results

EDEN PRAIRIE, MN, Nov. 08, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call on Friday, November 10, 2023, at 8:00AM (ET) to present the Q3 2023 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Listening: 1-877-407-0784 or 1-201-689-8560 Conference ID number : 13742652 OR click the Call me™ link for instant telephone access to the event.https://callme.viavid.com/viavid/?callme=true&passcode=13732361&h=true&info=company&r=true&B=6 Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. A replay will be made available...

Continue reading

CNH Industrial: Completion of $300 million Buyback Program

Basildon, November 8, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that it has completed its sixth and final $50 million tranche (the “Sixth Tranche”) of its $300 million share buyback program. The Company completed transactions in the period October 30 through November 6, 2023, reported in aggregate, based on automatic orders placed with the Company’s broker (who has made its trading decisions as to the timing of the purchases independently of the Company and on the basis of instructions given before the commencement of the Company’s closed period under the applicable regulations) as set forth in the table below. After the purchases announced today and considering those previously executed under the Sixth Tranche, the total invested amount in the Sixth Tranche is approximately €46,768,174.09 ($50,000,004.01) or a total...

Continue reading

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at the Stifel 2023 Healthcare Conference on Wednesday, November 15th at 11:30 am ET. Disc will also give presentations at the Jefferies London Healthcare Conference on Thursday, November 16th at 9:30 am GMT / 4:30 am ET and the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30th at 2:30 pm ET. A live webcast of the presentations will be available through the investor relations section of the Company’s website at ir.discmedicine.com and an archived replay will be...

Continue reading

WEST MINING ANNOUNCES PROPOSED SHARE CONSOLIDATION

Vancouver, BC, Nov. 08, 2023 (GLOBE NEWSWIRE) — West Mining Corp. (“West” or the “Company”) (CSE: WEST) (OTC: WESMF) announces that it will complete a consolidation of the authorized and issued common shares of the Company (the “Common Shares”) on the basis of a one post-consolidated Common Share for each ten pre-consolidation Common Shares (the “Consolidation”). Prior to the Consolidation, the Company has 61,627,312 pre-Consolidation Common Shares issued and outstanding. Following the Consolidation, the Company will have approximately 6,162,731 post-Consolidation Common Shares issued and outstanding. No fractional Common Shares will be issued upon the Consolidation. In the event a holder of Common Shares would otherwise be entitled to receive a fractional Common Share in connection with the Consolidation, the number of Common...

Continue reading

BurgerFi to Report Third Quarter 2023 Financial Results on November 15, 2023

FORT LAUDERDALE, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) — BurgerFi International, Inc. (NASDAQ: BFI, BFIIW) (“BurgerFi”), owner of one of the nation’s leading fast-casual “better burger” dining concepts through the BurgerFi brand, and the high-quality, casual dining pizza brand under the name Anthony’s Coal Fired Pizza & Wings (“Anthony’s”), will report financial results for the third quarter ended October 2, 2023 on Wednesday, November 15, 2023 before the market opens. Management will host a conference call at 8:30 a.m. Eastern time on the same day to discuss the results.   The conference call will be broadcast live and available for replay on the Company’s Investor Relations website at ir.burgerfi.com. Participants can also access the call using the dial-in details below. Date: Wednesday, November 15, 2023Time: 8:30 a.m. ETToll-free...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.